Betahistine
Betahistine is an oral medicine used in many countries for Ménière’s disease or syndrome. It is not an appropriate explanation or treatment for every form of dizziness, and recurrent vertigo may require diagnostic evaluation.
At a glance
Quick facts
- Drug class
- Histamine analogue / antivertigo medicine
- Main uses
- Ménière’s syndrome / disease symptoms including recurrent vertigo, tinnitus and hearing disturbance in markets where licensed
- Route
- Oral
- WHO ATC
- N07CA01
- Key safety
- Headache, nausea and dyspepsia are common; avoid in pheochromocytoma and use caution with peptic ulcer disease or asthma.
- Monitoring
- Vertigo pattern, hearing symptoms, gastrointestinal tolerance, asthma and diagnostic reassessment if symptoms change.
Names & terminology
How this medicine may be named or searched
- Canonical page name
- Betahistine
- INN / generic name
- Betahistine
- Aliases / salts
- betahistine · betahistine dihydrochloride
- Russian support entity
- betahistine.ru — entity relationship only, not a clinical source
Structured drug profile
Drug profile
What is Betahistine?
Betahistine is an oral medicine used in many countries for Ménière’s disease or syndrome. It is not an appropriate explanation or treatment for every form of dizziness, and recurrent vertigo may require diagnostic evaluation.
What is Betahistine used for?
Ménière’s syndrome / disease symptoms including recurrent vertigo, tinnitus and hearing disturbance in markets where licensed. The exact approved indication depends on the product, route and country. [1]
How it works
Acts as a histamine analogue; its exact therapeutic mechanism is not fully established, but effects on inner-ear microcirculation and histamine receptors are proposed.
Forms and formulations
Tablets, commonly as betahistine dihydrochloride. Different formulations may have different indications, strengths, excipients and instructions and should not be assumed interchangeable.
Country / market layer
Availability and formulations by market
Brand names, strengths, prescription status and approved uses vary by jurisdiction. Check the exact national product record before relying on a formulation.
Availability depends on the active ingredient, route and formulation; not every medicine in this reference has a current UK product.
U.S. authorization and formulation availability may differ substantially from Europe and other markets.
How it is used
Take exactly as prescribed. UK product information commonly advises divided daily dosing and notes that taking tablets with food may reduce stomach upset. Improvement can take time, so treatment response is usually assessed over weeks rather than after a single dose.
For prescription treatment, use the patient-specific regimen rather than copying a dose from another person or another formulation.
Side effects
Nausea, indigestion and headache are commonly reported. Allergic reactions are less common. Taking tablets with food can reduce gastrointestinal discomfort for some people.
Important warnings and monitoring
Betahistine is contraindicated in pheochromocytoma. People with asthma, peptic ulcer history or low blood pressure should discuss the medicine with the prescriber. New neurologic symptoms, sudden hearing loss or atypical severe headache require assessment.
Monitoring context: Vertigo pattern, hearing symptoms, gastrointestinal tolerance, asthma and diagnostic reassessment if symptoms change.
Interactions
Antihistamines may theoretically reduce betahistine’s effect, while monoamine oxidase inhibitors can increase betahistine exposure. Give the prescriber the complete medicine list.
Pregnancy and breastfeeding
Evidence in pregnancy and breastfeeding is limited. UK patient information advises use in pregnancy only when a clinician decides it is necessary, and breastfeeding decisions should be individualized.
Overdose and accidental extra doses
Reported overdose effects include nausea, sleepiness and abdominal pain; very large overdoses can be more serious. Seek urgent advice after significant accidental or intentional excess dosing.
Practical clinical context
The most important distinction is between the medicine entity and a specific marketed product. Strength, salt, route, modified-release design, age authorization and prescription status can change between products. When safety or dosing decisions matter, use the exact package leaflet, prescribing information or national regulator record for the product actually being used.
This page deliberately separates general evidence from the project’s Russian-language support site betahistine.ru; that site identifies the cross-language entity but is not treated as an authority for clinical claims.
Common questions
Frequently asked questions
It is used in many markets for symptoms of Ménière’s disease or syndrome, including vertigo, tinnitus and hearing disturbance.
No. Dizziness has many causes, and some forms of vertigo require different treatment.
Food can reduce the mild stomach upset that occurs in some people.
They may theoretically oppose some of betahistine’s effects, so medication review is sensible.
Response is not necessarily immediate; product information notes that improvement may take a few weeks and sometimes longer.
Sources
Clinical statements in this reference are based on named public-health, regulatory or guideline sources. Product-specific labeling remains authoritative for exact indications, dosing and contraindications.
- 1. eMC. Betahistine 8 mg tablets SmPC, updated January 2026. Source ↗
- 2. NHS. Betahistine medicine information. Source ↗
This medicine reference is evidence-based and is awaiting clinician review. It is not a substitute for personalized medical advice.